Before taking Hemlibra(Emicizumab)

Caution is advised when using aPCC concurrently due to thrombotic risks.

Important Safety Information

HEMLIBRA may increase the risk of thrombotic events when combined with activated prothrombin complex concentrate (aPCC) at cumulative doses exceeding 100 U/kg/24 hours. It also interferes with certain coagulation tests, which may lead to inaccurate results.